Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009189 | 0.87 | PPARG (0.48) | CYSLTR2CYSLTR1ABCB1PPARGPPARD | |
| SCHEMBL2010807 | 0.84 | SMN1; SMN2 (0.57) | ABCB1LMNAMAPTCYP2C9 | |
| SCHEMBL2008607 | 0.82 | SYK (0.43) | CYSLTR2CYSLTR1ABCB1PPARGPPARD | |
| SCHEMBL2012527 | 0.77 | CASP3 (0.45) | ABCB1PPARGPPARDPPARALMNA | |
| SCHEMBL9120538 | 0.76 | MAPT (0.67) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL2010825 | 0.76 | PRMT5 (0.34) | CYSLTR2CYSLTR1PPARGPPARDPPARA | |
| SCHEMBL2013330 | 0.75 | PPARG (0.48) | CYSLTR2CYSLTR1ABCB1PPARGPPARD | |
| SCHEMBL7041460 | 0.74 | MAPT (0.51) | CYSLTR2CYSLTR1MAPTCYP2C9 | |
| SCHEMBL2009004 | 0.74 | HPGD (0.55) | PPARDLMNAMAPT | |
| SCHEMBL6933049 | 0.74 | CTSD (0.58) | CYSLTR2CYSLTR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | CYSLTR2 240/4885CYSLTR1 229/4885ABCB1 568/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | CYSLTR2 240/4885CYSLTR1 229/4885ABCB1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.